PMC:7319621 / 2944-4405 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T29","span":{"begin":346,"end":366},"obj":"CHEBI:78021;CHEBI:78021"},{"id":"T30","span":{"begin":690,"end":699},"obj":"CHEBI:33234;CHEBI:33234"},{"id":"T31","span":{"begin":700,"end":707},"obj":"CHEBI:30089;CHEBI:30089"},{"id":"T32","span":{"begin":753,"end":762},"obj":"CHEBI:33234;CHEBI:33234"},{"id":"T33","span":{"begin":763,"end":770},"obj":"CHEBI:30089;CHEBI:30089"},{"id":"T34","span":{"begin":1227,"end":1235},"obj":"SP_7"},{"id":"T35","span":{"begin":1357,"end":1365},"obj":"SP_7"},{"id":"T36","span":{"begin":1368,"end":1379},"obj":"NCBITaxon:11118"},{"id":"T37","span":{"begin":1449,"end":1453},"obj":"UBERON:0002048"},{"id":"T55528","span":{"begin":346,"end":366},"obj":"CHEBI:78021;CHEBI:78021"},{"id":"T12639","span":{"begin":690,"end":699},"obj":"CHEBI:33234;CHEBI:33234"},{"id":"T2367","span":{"begin":700,"end":707},"obj":"CHEBI:30089;CHEBI:30089"},{"id":"T17262","span":{"begin":753,"end":762},"obj":"CHEBI:33234;CHEBI:33234"},{"id":"T9485","span":{"begin":763,"end":770},"obj":"CHEBI:30089;CHEBI:30089"},{"id":"T802","span":{"begin":1227,"end":1235},"obj":"SP_7"},{"id":"T10205","span":{"begin":1357,"end":1365},"obj":"SP_7"},{"id":"T30814","span":{"begin":1368,"end":1379},"obj":"NCBITaxon:11118"},{"id":"T73131","span":{"begin":1449,"end":1453},"obj":"UBERON:0002048"}],"text":"Our case series highlights several important features. Whereas the nationwide total of EVALI cases has faded in recent months, we have observed an uptick in Utah (Fig 1 ). Several patients reported substantial anxiety, which is a frequent comorbidity in EVALI,5 which led them to vape more to cope with pandemic stressors. Their agent of choice, tetrahydrocannabinol oil, remains outlawed in many states including Utah, which indicates that patients may obtain it through unregulated sources. Ongoing investigations by federal authorities shed doubt on one distinct causal agent,1 , 7 which suggests that the causes may be heterogenous and that cases may persist despite efforts to curtail vitamin E acetate. We definitively linked only two patients to vitamin E acetate through state laboratory testing. This convergence of social and medical factors suggests that we will continue to see patients with EVALI for the foreseeable future.\nFigure 1 Frequency of reported patients with EVALI by month of diagnosis. Data presented through May 15, 2020. The first case of EVALI in our cohorts was reported June 24, 2019. The first case in this case series with negative COVID testing was diagnosed March 17, 2020. The first case of COVID-19 diagnosed in Utah was March 6, 2020. May 2020 is highlighted because data are incomplete and current as of May 15, 2020. COVID-19 = coronavirus disease 2019; EVALI = e-cigarette, or vaping, product use-associated lung injury."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":1449,"end":1453},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Our case series highlights several important features. Whereas the nationwide total of EVALI cases has faded in recent months, we have observed an uptick in Utah (Fig 1 ). Several patients reported substantial anxiety, which is a frequent comorbidity in EVALI,5 which led them to vape more to cope with pandemic stressors. Their agent of choice, tetrahydrocannabinol oil, remains outlawed in many states including Utah, which indicates that patients may obtain it through unregulated sources. Ongoing investigations by federal authorities shed doubt on one distinct causal agent,1 , 7 which suggests that the causes may be heterogenous and that cases may persist despite efforts to curtail vitamin E acetate. We definitively linked only two patients to vitamin E acetate through state laboratory testing. This convergence of social and medical factors suggests that we will continue to see patients with EVALI for the foreseeable future.\nFigure 1 Frequency of reported patients with EVALI by month of diagnosis. Data presented through May 15, 2020. The first case of EVALI in our cohorts was reported June 24, 2019. The first case in this case series with negative COVID testing was diagnosed March 17, 2020. The first case of COVID-19 diagnosed in Utah was March 6, 2020. May 2020 is highlighted because data are incomplete and current as of May 15, 2020. COVID-19 = coronavirus disease 2019; EVALI = e-cigarette, or vaping, product use-associated lung injury."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T3","span":{"begin":1449,"end":1453},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Our case series highlights several important features. Whereas the nationwide total of EVALI cases has faded in recent months, we have observed an uptick in Utah (Fig 1 ). Several patients reported substantial anxiety, which is a frequent comorbidity in EVALI,5 which led them to vape more to cope with pandemic stressors. Their agent of choice, tetrahydrocannabinol oil, remains outlawed in many states including Utah, which indicates that patients may obtain it through unregulated sources. Ongoing investigations by federal authorities shed doubt on one distinct causal agent,1 , 7 which suggests that the causes may be heterogenous and that cases may persist despite efforts to curtail vitamin E acetate. We definitively linked only two patients to vitamin E acetate through state laboratory testing. This convergence of social and medical factors suggests that we will continue to see patients with EVALI for the foreseeable future.\nFigure 1 Frequency of reported patients with EVALI by month of diagnosis. Data presented through May 15, 2020. The first case of EVALI in our cohorts was reported June 24, 2019. The first case in this case series with negative COVID testing was diagnosed March 17, 2020. The first case of COVID-19 diagnosed in Utah was March 6, 2020. May 2020 is highlighted because data are incomplete and current as of May 15, 2020. COVID-19 = coronavirus disease 2019; EVALI = e-cigarette, or vaping, product use-associated lung injury."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T23","span":{"begin":210,"end":217},"obj":"Disease"},{"id":"T25","span":{"begin":1227,"end":1235},"obj":"Disease"},{"id":"T26","span":{"begin":1357,"end":1365},"obj":"Disease"},{"id":"T27","span":{"begin":1368,"end":1392},"obj":"Disease"},{"id":"T28","span":{"begin":1454,"end":1460},"obj":"Disease"}],"attributes":[{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005618"},{"id":"A24","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0011918"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"Our case series highlights several important features. Whereas the nationwide total of EVALI cases has faded in recent months, we have observed an uptick in Utah (Fig 1 ). Several patients reported substantial anxiety, which is a frequent comorbidity in EVALI,5 which led them to vape more to cope with pandemic stressors. Their agent of choice, tetrahydrocannabinol oil, remains outlawed in many states including Utah, which indicates that patients may obtain it through unregulated sources. Ongoing investigations by federal authorities shed doubt on one distinct causal agent,1 , 7 which suggests that the causes may be heterogenous and that cases may persist despite efforts to curtail vitamin E acetate. We definitively linked only two patients to vitamin E acetate through state laboratory testing. This convergence of social and medical factors suggests that we will continue to see patients with EVALI for the foreseeable future.\nFigure 1 Frequency of reported patients with EVALI by month of diagnosis. Data presented through May 15, 2020. The first case of EVALI in our cohorts was reported June 24, 2019. The first case in this case series with negative COVID testing was diagnosed March 17, 2020. The first case of COVID-19 diagnosed in Utah was March 6, 2020. May 2020 is highlighted because data are incomplete and current as of May 15, 2020. COVID-19 = coronavirus disease 2019; EVALI = e-cigarette, or vaping, product use-associated lung injury."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T21","span":{"begin":99,"end":102},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T22","span":{"begin":228,"end":229},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T23","span":{"begin":796,"end":803},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T24","span":{"begin":1171,"end":1182},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T25","span":{"begin":1449,"end":1453},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T26","span":{"begin":1449,"end":1453},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Our case series highlights several important features. Whereas the nationwide total of EVALI cases has faded in recent months, we have observed an uptick in Utah (Fig 1 ). Several patients reported substantial anxiety, which is a frequent comorbidity in EVALI,5 which led them to vape more to cope with pandemic stressors. Their agent of choice, tetrahydrocannabinol oil, remains outlawed in many states including Utah, which indicates that patients may obtain it through unregulated sources. Ongoing investigations by federal authorities shed doubt on one distinct causal agent,1 , 7 which suggests that the causes may be heterogenous and that cases may persist despite efforts to curtail vitamin E acetate. We definitively linked only two patients to vitamin E acetate through state laboratory testing. This convergence of social and medical factors suggests that we will continue to see patients with EVALI for the foreseeable future.\nFigure 1 Frequency of reported patients with EVALI by month of diagnosis. Data presented through May 15, 2020. The first case of EVALI in our cohorts was reported June 24, 2019. The first case in this case series with negative COVID testing was diagnosed March 17, 2020. The first case of COVID-19 diagnosed in Utah was March 6, 2020. May 2020 is highlighted because data are incomplete and current as of May 15, 2020. COVID-19 = coronavirus disease 2019; EVALI = e-cigarette, or vaping, product use-associated lung injury."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T9","span":{"begin":690,"end":699},"obj":"Chemical"},{"id":"T10","span":{"begin":690,"end":697},"obj":"Chemical"},{"id":"T11","span":{"begin":700,"end":707},"obj":"Chemical"},{"id":"T13","span":{"begin":753,"end":762},"obj":"Chemical"},{"id":"T14","span":{"begin":753,"end":760},"obj":"Chemical"},{"id":"T15","span":{"begin":763,"end":770},"obj":"Chemical"}],"attributes":[{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_33234"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_33229"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_30089"},{"id":"A12","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_47622"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_33234"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_33229"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_30089"},{"id":"A16","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_47622"}],"text":"Our case series highlights several important features. Whereas the nationwide total of EVALI cases has faded in recent months, we have observed an uptick in Utah (Fig 1 ). Several patients reported substantial anxiety, which is a frequent comorbidity in EVALI,5 which led them to vape more to cope with pandemic stressors. Their agent of choice, tetrahydrocannabinol oil, remains outlawed in many states including Utah, which indicates that patients may obtain it through unregulated sources. Ongoing investigations by federal authorities shed doubt on one distinct causal agent,1 , 7 which suggests that the causes may be heterogenous and that cases may persist despite efforts to curtail vitamin E acetate. We definitively linked only two patients to vitamin E acetate through state laboratory testing. This convergence of social and medical factors suggests that we will continue to see patients with EVALI for the foreseeable future.\nFigure 1 Frequency of reported patients with EVALI by month of diagnosis. Data presented through May 15, 2020. The first case of EVALI in our cohorts was reported June 24, 2019. The first case in this case series with negative COVID testing was diagnosed March 17, 2020. The first case of COVID-19 diagnosed in Utah was March 6, 2020. May 2020 is highlighted because data are incomplete and current as of May 15, 2020. COVID-19 = coronavirus disease 2019; EVALI = e-cigarette, or vaping, product use-associated lung injury."}

{"project":"LitCovid-PubTator","denotations":[{"id":"85","span":{"begin":969,"end":977},"obj":"Species"},{"id":"86","span":{"begin":1165,"end":1170},"obj":"Disease"},{"id":"87","span":{"begin":1227,"end":1235},"obj":"Disease"},{"id":"88","span":{"begin":1368,"end":1392},"obj":"Disease"},{"id":"89","span":{"begin":1449,"end":1460},"obj":"Disease"},{"id":"98","span":{"begin":180,"end":188},"obj":"Species"},{"id":"99","span":{"begin":441,"end":449},"obj":"Species"},{"id":"100","span":{"begin":741,"end":749},"obj":"Species"},{"id":"101","span":{"begin":890,"end":898},"obj":"Species"},{"id":"102","span":{"begin":346,"end":370},"obj":"Chemical"},{"id":"103","span":{"begin":690,"end":707},"obj":"Chemical"},{"id":"104","span":{"begin":753,"end":770},"obj":"Chemical"},{"id":"105","span":{"begin":210,"end":217},"obj":"Disease"}],"attributes":[{"id":"A85","pred":"tao:has_database_id","subj":"85","obj":"Tax:9606"},{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"MESH:C000657245"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"MESH:C000657245"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"MESH:C000657245"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"MESH:D055370"},{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"Tax:9606"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"Tax:9606"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"Tax:9606"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"Tax:9606"},{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"MESH:D024502"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"MESH:D024502"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"MESH:D001007"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Our case series highlights several important features. Whereas the nationwide total of EVALI cases has faded in recent months, we have observed an uptick in Utah (Fig 1 ). Several patients reported substantial anxiety, which is a frequent comorbidity in EVALI,5 which led them to vape more to cope with pandemic stressors. Their agent of choice, tetrahydrocannabinol oil, remains outlawed in many states including Utah, which indicates that patients may obtain it through unregulated sources. Ongoing investigations by federal authorities shed doubt on one distinct causal agent,1 , 7 which suggests that the causes may be heterogenous and that cases may persist despite efforts to curtail vitamin E acetate. We definitively linked only two patients to vitamin E acetate through state laboratory testing. This convergence of social and medical factors suggests that we will continue to see patients with EVALI for the foreseeable future.\nFigure 1 Frequency of reported patients with EVALI by month of diagnosis. Data presented through May 15, 2020. The first case of EVALI in our cohorts was reported June 24, 2019. The first case in this case series with negative COVID testing was diagnosed March 17, 2020. The first case of COVID-19 diagnosed in Utah was March 6, 2020. May 2020 is highlighted because data are incomplete and current as of May 15, 2020. COVID-19 = coronavirus disease 2019; EVALI = e-cigarette, or vaping, product use-associated lung injury."}

{"project":"LitCovid-sentences","denotations":[{"id":"T18","span":{"begin":0,"end":54},"obj":"Sentence"},{"id":"T19","span":{"begin":55,"end":171},"obj":"Sentence"},{"id":"T20","span":{"begin":172,"end":322},"obj":"Sentence"},{"id":"T21","span":{"begin":323,"end":492},"obj":"Sentence"},{"id":"T22","span":{"begin":493,"end":708},"obj":"Sentence"},{"id":"T23","span":{"begin":709,"end":804},"obj":"Sentence"},{"id":"T24","span":{"begin":805,"end":937},"obj":"Sentence"},{"id":"T25","span":{"begin":938,"end":1011},"obj":"Sentence"},{"id":"T26","span":{"begin":1012,"end":1048},"obj":"Sentence"},{"id":"T27","span":{"begin":1049,"end":1115},"obj":"Sentence"},{"id":"T28","span":{"begin":1116,"end":1208},"obj":"Sentence"},{"id":"T29","span":{"begin":1209,"end":1272},"obj":"Sentence"},{"id":"T30","span":{"begin":1273,"end":1356},"obj":"Sentence"},{"id":"T31","span":{"begin":1357,"end":1461},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Our case series highlights several important features. Whereas the nationwide total of EVALI cases has faded in recent months, we have observed an uptick in Utah (Fig 1 ). Several patients reported substantial anxiety, which is a frequent comorbidity in EVALI,5 which led them to vape more to cope with pandemic stressors. Their agent of choice, tetrahydrocannabinol oil, remains outlawed in many states including Utah, which indicates that patients may obtain it through unregulated sources. Ongoing investigations by federal authorities shed doubt on one distinct causal agent,1 , 7 which suggests that the causes may be heterogenous and that cases may persist despite efforts to curtail vitamin E acetate. We definitively linked only two patients to vitamin E acetate through state laboratory testing. This convergence of social and medical factors suggests that we will continue to see patients with EVALI for the foreseeable future.\nFigure 1 Frequency of reported patients with EVALI by month of diagnosis. Data presented through May 15, 2020. The first case of EVALI in our cohorts was reported June 24, 2019. The first case in this case series with negative COVID testing was diagnosed March 17, 2020. The first case of COVID-19 diagnosed in Utah was March 6, 2020. May 2020 is highlighted because data are incomplete and current as of May 15, 2020. COVID-19 = coronavirus disease 2019; EVALI = e-cigarette, or vaping, product use-associated lung injury."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":210,"end":217},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0000739"}],"text":"Our case series highlights several important features. Whereas the nationwide total of EVALI cases has faded in recent months, we have observed an uptick in Utah (Fig 1 ). Several patients reported substantial anxiety, which is a frequent comorbidity in EVALI,5 which led them to vape more to cope with pandemic stressors. Their agent of choice, tetrahydrocannabinol oil, remains outlawed in many states including Utah, which indicates that patients may obtain it through unregulated sources. Ongoing investigations by federal authorities shed doubt on one distinct causal agent,1 , 7 which suggests that the causes may be heterogenous and that cases may persist despite efforts to curtail vitamin E acetate. We definitively linked only two patients to vitamin E acetate through state laboratory testing. This convergence of social and medical factors suggests that we will continue to see patients with EVALI for the foreseeable future.\nFigure 1 Frequency of reported patients with EVALI by month of diagnosis. Data presented through May 15, 2020. The first case of EVALI in our cohorts was reported June 24, 2019. The first case in this case series with negative COVID testing was diagnosed March 17, 2020. The first case of COVID-19 diagnosed in Utah was March 6, 2020. May 2020 is highlighted because data are incomplete and current as of May 15, 2020. COVID-19 = coronavirus disease 2019; EVALI = e-cigarette, or vaping, product use-associated lung injury."}